Skip to main content

Advertisement

Table 3 Prevalence of various components of the metabolic syndrome among the 9795 randomized participants in the FIELD study

From: Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]

Metabolic syndrome feature: ATPIII criteria * Men (n= 6138) Women (n= 3657) Total (n= 9795)
n % n % n %
Waist measurement (women >88 cm; men >102 cm) 3613 58.9 3034 83.0 6647 67.9
Triglycerides >= 1.7 mmol/L 3073 50.1 2020 55.2 5093 52.0
HDL (men <40 mg/dL; women <50 mg/dL) 3365 54.8 2455 67.1 5820 59.4
Hypertension (SBP >= 130 and DBP >= 85 mm Hg) 5050 82.3 3131 85.6 8181 83.5
Fasting glucose >= 110 mg/dL or diabetes 6133 99.9 3646 99.7 9779 99.8
  1. * When 3 of the 5 listed characteristics are present, a diagnosis of metabolic syndrome is established (84% of the cohort met the criteria)